“There are many blood cancers, completely different, and therefore also with different prognoses. T.r the most frequent are lymphomas, for which 70-80% of patients are cured today, regardless of gender and other characteristics. For other diseases, such as myeloma and myelodysplasias, we have obtained a very clear prolongation of life thanks to new drugs so in leukemia we are witnessing in recent years a revolution with a highly significant improvement in the percentage of healed “. Like this Armando Santorodirector of the Humanitas Cancer Center at the Humanitas Irccs Clinical Institute in Rozzano, speaking this morning at the press conference for the presentation of “Cancer: The new frontiers of treatments in oncology and hematology”, a scientific event organized in Rome by AstraZeneca, at the Congress Center ‘The cloud’.
“Precision medicine – explains the oncologist – it is increasingly having practical application, there are many patients today with solid tumors and haematological diseases who are treated in a completely different way compared to 5-10 years ago with specific drugs capable of obtaining in many conditions a marked improvement in therapeutic results and in the duration of the responses. We are certainly witnessing a highly positive evolution ”. To date, “many patients suffering from different haematological diseases are treated with molecular therapies or immunotherapy – underlines Santoro -. There is no week or month in which there is no new pathology for which an indication is given, following extremely favorable results, for the use of new therapies that in most cases supplant the old treatments used ” .
And regarding theacalabrutinibamong the themes that emerged from the meeting, Santoro has no doubts: “E‘a very interesting molecular target therapy currently used in chronic lymphatic leukemia. We in Humanitas have been using it regularly for some time, also because we have used it in the experimentation phase ”. It is “a molecule with an extremely interesting profile both in terms of responses and in terms of toxicity that will become one of the fundamental weapons for the treatment of chronic lymphatic leukemia”, he concludes.
#Santoro #Humanitas #Today #patients #lymphomas #recover